In a clinical trial, it frequently occurs that the most credible outcome to evaluate the effectiveness of a new therapy (the true endpoint) is difficult to measure. In such a situation, it can be an effective strategy to replace the true endpoint by a (bio)marker that is easier to measure and that allows for a prediction of the treatment effect on the true endpoint (a surrogate endpoint). The package 'Surrogate' allows for an evaluation of the appropriateness of a candidate surrogate endpoint based on the meta-analytic, information-theoretic, and causal-inference frameworks. Part of this software has been developed using funding provided from the European Union's Seventh Framework Programme for research, technological development and demonstration (Grant Agreement no 602552), the Special Research Fund (BOF) of Hasselt University (BOF-number: BOF2OCPO3), GlaxoSmithKline Biologicals, Baekeland Mandaat (HBC.2022.0145), and Johnson & Johnson Innovative Medicine.
Maintainer: Wim Van Der Elst wim.vanderelst@gmail.com
Authors:
Florian Stijven florian.stijven@kuleuven.be
Fenny Ong
Dries De Witte
Paul Meyvisch
Alvaro Poveda
Ariel Alonso
Hannah Ensor
Christoper Weir
Geert Molenberghs
Useful links: